Michael J. Duffy

North Carolina State University — United States

Medicine · Health Sciences

85h-index26.4kcitations353works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(66), Protease and Inhibitor Mechanisms(46), Estrogen and related hormone effects(37), Cancer Genomics and Diagnostics(34), Peptidase Inhibition and Analysis(33)

Publications353 total

Histology and expressions/localizations of estrogen and progesterone receptors in the reproductive tract during the natural ovarian cycle of female domestic cats ovulating spontaneously
Theriogenology·2025
Circulating tumor DNA (ctDNA): can it be used as a pan-cancer early detection test?
Critical Reviews in Clinical Laboratory Sciences·2023· 14 cited
Comparing functional and quality of life outcomes in transcatheter aortic valve implantation and surgical aortic valve replacement for aortic stenosis: a systematic review and meta-analysis
BMC Cardiovascular Disorders·2023· 11 citedOpen Access
Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: Early detection, monitoring and therapy prediction
Tumor Biology·2023· 49 citedOpen Access
Degradation of MYC by the mutant p53 reactivator drug, COTI-2 in breast cancer cells
Investigational New Drugs·2023· 8 citedOpen Access
Data from Altered Cytoplasmic-to-Nuclear Ratio of Survivin Is a Prognostic Indicator in Breast Cancer
2023Open Access
Supplementary Table 1 from Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib
2023Open Access
Supplementary Table 2 from Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib
2023Open Access
Supplementary Table 1 from CA IX is an Independent Prognostic Marker in Premenopausal Breast Cancer Patients with One to Three Positive Lymph Nodes and a Putative Marker of Radiation Resistance
2023Open Access
Data from Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib
2023Open Access
Supplementary Table 1 from CA IX is an Independent Prognostic Marker in Premenopausal Breast Cancer Patients with One to Three Positive Lymph Nodes and a Putative Marker of Radiation Resistance
2023Open Access
Data from CA IX is an Independent Prognostic Marker in Premenopausal Breast Cancer Patients with One to Three Positive Lymph Nodes and a Putative Marker of Radiation Resistance
2023Open Access
Supplementary Table 2 from Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib
2023Open Access
Supplementary Data from Altered Cytoplasmic-to-Nuclear Ratio of Survivin Is a Prognostic Indicator in Breast Cancer
2023Open Access
Data from Altered Cytoplasmic-to-Nuclear Ratio of Survivin Is a Prognostic Indicator in Breast Cancer
2023Open Access
Data from Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib
2023Open Access
Data from CA IX is an Independent Prognostic Marker in Premenopausal Breast Cancer Patients with One to Three Positive Lymph Nodes and a Putative Marker of Radiation Resistance
2023Open Access
Vitamin D Supplementation: Does It Have a Preventative or Therapeutic Role in Cancer?
Nutrition and Cancer·2022· 10 cited
Targeting Mutant p53 for Cancer Treatment: Moving Closer to Clinical Use?
Cancers·2022· 42 citedOpen Access
Circulating Tumor DNA as a Biomarker for Monitoring Patients with Solid Cancers: Comparison with Standard Protein Biomarkers
Clinical Chemistry·2022· 50 citedOpen Access
page 1 of 18Next →

Frequent Co-authors

John Crown(12), N. J. O’Higgins(8), R. Lamerz(7), Norma O’Donovan(7), Patricia M. McGowan(6), Caj Haglund(5), Enda McDermott(5), Catharine M. Sturgeon(4), Nadia Harbeck(4), Teresa Maguire(4), Andrea Nicolini(4), Naoise C. Synnott(4), György Sölétormos(3), Catherine Duggan(3), C. Sturgeon(3), Ondřej Topolčan(3), William M. Gallagher(3), Peter A. Andreasen(2), Nils Brünner(2), Robert C. Bast(2)